Effectiveness and safety of carbon ion radiotherapy for stage III non-small cell lung cancer: a single-center retrospective study - Scorecard - MDSpire
Advertisement
Effectiveness and safety of carbon ion radiotherapy for stage III non-small cell lung cancer: a single-center retrospective study
Clinical Scorecard: Assessment of Carbon Ion Radiotherapy's Efficacy and Safety in Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis from a Single Institution
At a Glance
Category
Detail
Condition
Stage III Non-Small Cell Lung Cancer
Key Mechanisms
Carbon ion radiotherapy (CIRT) utilizes the Bragg peak for precise tumor targeting while minimizing damage to surrounding tissues.
Target Population
Patients with histopathologically confirmed stage III NSCLC, inoperable tumors, or those who refused surgery.
Care Setting
Retrospective analysis conducted at Wuwei Cancer Hospital in Gansu Province.
Key Highlights
1-year overall survival (OS) rate of 85.4%, progression-free survival (PFS) rate of 79.8%, and local control (LRC) rate of 95.3%.
2-year OS rate of 65.9%, PFS rate of 50.8%, and LRC rate of 82.9%.
Grade 1 radiation esophagitis observed in 43.9% of patients; grade 3 lymphopenia was the most common severe adverse reaction.
CIRT combined with immunotherapy significantly improves overall survival.
Median follow-up duration of 31.5 months.
Guideline-Based Recommendations
Diagnosis
Clinical staging based on the TNM system from the 8th edition of the AJCC Cancer Staging Manual.
Management
CIRT is recommended for inoperable stage III NSCLC, potentially combined with immunotherapy.
Monitoring & Follow-up
Follow-up assessments should include evaluation of overall survival, progression-free survival, and local control rates.
Risks
Adverse events include radiation pneumonitis, esophagitis, dermatitis, and hematologic reactions.
Patient & Prescribing Data
82 patients diagnosed with stage III NSCLC treated with CIRT.
CIRT doses ranged from 48 to 78 Gy (RBE), with manageable adverse reactions.
Clinical Best Practices
Utilize CIRT for precise tumor targeting in stage III NSCLC.
Consider combining CIRT with immunotherapy to enhance survival outcomes.
Monitor patients for adverse reactions using CTCAE version 5.0.
